
GL Stock Forecast & Price Target
GL Analyst Ratings
Bulls say
Globe Life Inc. is projected to achieve life premium growth of 4.0%-4.5% and a significant 14%-16% rise in health premiums in the coming year, driven by an anticipated 10% increase in leads for its exclusive agencies. Management has reported favorable mortality experience, contributing to a 3Q remeasurement gain of $150 million, with Life gains reaching $18 million, which reflects the strong performance trajectory of the company's insurance products. Furthermore, the company has increased its 2025 earnings per share (EPS) estimate to $14.50 and maintained a forecast of $15.05 for 2026, reinforcing investor confidence in its long-term growth expectations.
Bears say
Globe Life Inc is facing a negative outlook primarily due to projected operating earnings per share growth of only 3% at the midpoint for 2026, which is significantly lower than its historical average, partly because of anticipated reduced life remeasurement gains. Additionally, the company encounters multiple risks including potential fines or reputational damage from an ongoing EEOC review, heightened margin pressure from increased health utilization, and challenges in recruiting an effective salesforce that could hinder revenue prospects. Furthermore, while the company's underwriting margins are expected to decrease, the shift toward Medicare Supplement products—despite low capital requirements—indicates potential profitability concerns given their lower profit margins.
This aggregate rating is based on analysts' research of Globe Life Inc and is not a guaranteed prediction by Public.com or investment advice.
GL Analyst Forecast & Price Prediction
Start investing in GL
Order type
Buy in
Order amount
Est. shares
0 shares